logo
Sacramento's Ten Acres Pharmacy to close its doors after 5 years

Sacramento's Ten Acres Pharmacy to close its doors after 5 years

CBS News16-07-2025
Sacramento's Ten Acres Pharmacy announced that it is closing its doors after five years. This comes after big-box stores shut down hundreds of locations across the nation.
"I am a pharmacist. That is what I do," said Sonya Frausto, who owns Ten Acres Pharmacy in the Curtis Park/Land Park area. "Knowing that I can't take care of them anymore because of something that is not in my control is the worst of this whole decision."
Frausto said poor reimbursements from Pharmacy Benefit Managers, or PBMs, are to blame, and it's driving neighborhood pharmacies like hers out of business.
"This is a critical service in the community, and it's so sad to see it go away," said Mary Odbert, who came by the pharmacy to tell Frausto she was sorry.
Frausto said she started paying anywhere from 3 to 25 percent more for drugs, but insurance companies continued to pay her the same amount.
"We're looking at a future where there are going to be fewer and fewer brick and mortar pharmacies in people's neighborhoods," said democratic state senator Scott Wiener from San Francisco.
Weiner introduced a bill that would create a consistent rate across PBM reimbursements and prevent PBMs from pushing patients to use mail order.
"Health care should never be about money," said Frausto. "It should always be about care."
Frausto said this change could have saved her pharmacy had a similar bill passed last year.
Wiener told CBS13 that the bill is already gaining bipartisan support and believes the governor is backing it now, too.
"This year we've actually been working with the governor and put a piece of the bill into the budget," said Wiener.
Frausto said what she is going to miss most about the pharmacy is the people they serve. She said the final day of Ten Acres will be August 20.
"We see women who are pregnant and now their babies are five years old," said Frausto. "The reality is that I am going to miss taking care of people."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DealMakerInsider.com Publishes a New White Paper for M&A Advisors on Reframing Sell-Side Qualification in Tech
DealMakerInsider.com Publishes a New White Paper for M&A Advisors on Reframing Sell-Side Qualification in Tech

Yahoo

time26 minutes ago

  • Yahoo

DealMakerInsider.com Publishes a New White Paper for M&A Advisors on Reframing Sell-Side Qualification in Tech

INDEPENDENCE, Ohio, July 29, 2025 /PRNewswire/ -- today announces the release of an original thought-leadership paper, Reframing Sell-Side Qualification in Tech | What Unknown Exposures Advisors and Their Brokerages Experience. Authored by Art Howarth of M&A Evolution, this exclusive article offers seasoned M&A advisors actionable insights on brokering technology transactions. Powered by M&A Source® — the preeminent professional association dedicated to lower middle market mergers and acquisitions — delivers curated content to help experienced advisors drive more success. In his paper, Reframing Sell-Side Qualification in Tech | What Unknown Exposures Advisors and Their Brokerages Experience, Mr. Howarth writes, "Advisors should be very, very careful in technology transactions. Tech is certainly attractive when it comes to the multiples, but it can also be highly detrimental to your business future, resulting in future liabilities for you and your brokerage." Art Howarth holds a Bachelor of Computer Science (B. Comp Sci), from the faculty of Engineering & Computer Science at Concordia University. In this article, he shares expert insights on how to improve the qualification process, emphasizing the importance of: Understanding the production process Identifying the company lifecycle stage Assessing founder psychology During his 30+ year career, Art Howarth has had experience within a diverse set of public, private, and entrepreneurial roles spanning multiple continents and market areas. He was involved in 75 acquisitions and over 100 investments at Cisco Systems. As a leader of the Corporate Development Technology Group, his responsibilities covered tech strategy, investment portfolio tech extraction, technical due diligence for acquisitions/investments, and Intellectual Property (IP) evaluations. "M&A Source is the recognized source of opportunity and excellence for individuals and firms engaged in lower middle market business transactions. Our educational portal for experienced advisors, provides curated content and dealmaking insights to help them stay ahead of the curve." - Kylene Golubski, Executive Director, M&A Source Access these expert insights on About M&A Source M&A Source® is the leading not for profit association for individuals and firms engaged in lower middle market business transactions. The association provides education, benefits, conferences, support programs and networking opportunities, and awards the Mergers & Acquisitions Master Intermediary® (M&AMI®) designation to qualified advisors. For additional information, contact M&A Source directly at 216-243-0030. [Social Media Handles]Facebook - Twitter - - - - View original content to download multimedia: SOURCE M&A Source Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Medical Gas Market Forecast and Company Analysis Report 2025-2033 Featuring Air Liquide, Linde, Atlas Copco, Inox-Air, Taiyo Nippon Sanso, Matheson Tri-Gas, Horiba, Sol
Medical Gas Market Forecast and Company Analysis Report 2025-2033 Featuring Air Liquide, Linde, Atlas Copco, Inox-Air, Taiyo Nippon Sanso, Matheson Tri-Gas, Horiba, Sol

Yahoo

time26 minutes ago

  • Yahoo

Medical Gas Market Forecast and Company Analysis Report 2025-2033 Featuring Air Liquide, Linde, Atlas Copco, Inox-Air, Taiyo Nippon Sanso, Matheson Tri-Gas, Horiba, Sol

The Global Medical Gas Market is projected to grow from US$ 14.41 billion in 2024 to US$ 28.61 billion by 2033, with a CAGR of 7.92%. Key drivers include a shift toward home healthcare and telemedicine, rising chronic diseases, and advancements in medical technology. The Asia-Pacific region is expected to see the highest growth due to expanding healthcare sectors. The market faces challenges like stringent regulations and supply chain disruptions. High demand for portable solutions, growing telemedicine, and numerous chronic conditions are shaping the industry. Key players include Air Liquide, Linde PLC, and Atlas Copco Group. Medical Gas Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Medical Gas Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" report has been added to Global Medical Gas Market is expected to reach US$ 28.61 billion by 2033 from US$ 14.41 billion in 2024, with a CAGR of 7.92% from 2025 to 2033. Some of the key reasons driving the market are the growing tendency toward home healthcare and telemedicine, the prevalence of chronic illnesses including respiratory and cardiovascular diseases (CVDs), and many developments in medical technology. The aging population, rising rates of chronic respiratory conditions, and improvements in healthcare infrastructure are all contributing to the substantial expansion of the worldwide medical gas market. Medical gases, such as carbon dioxide, nitrous oxide, and oxygen, are necessary for a number of therapeutic and diagnostic uses in ambulatory surgery centers, home healthcare settings, and hospitals. The need for portable medical gas solutions, such oxygen concentrators, has increased due to the growing demand for home healthcare services. Due to growing healthcare sectors and government expenditures in medical infrastructure, the Asia-Pacific region is expected to develop at the highest rate, while North America already has a significant market share. The availability and distribution of medical gases may be impacted by supply chain interruptions and strict regulatory restrictions, which provide difficulties for the need for medicinal gases is also being fueled by the increasing incidence of asthma. The Australian Institute of Health and Welfare (AIHW) estimates that in 2023, asthma accounted for 35% of the entire burden related to all respiratory disorders and 2.5% of the overall illness burden. Nitrous oxide, carbon dioxide, nitrogen, oxygen, and medical air are some of the most often utilized medical gases in of the leading companies, Air Liquide Healthcare, provides medicinal gases to 20,000 hospitals and new healthcare facilities, and assists over 2 million people in managing chronic illnesses. Medical gases including heliox, oxygen, and lung gas mixes are widely employed in the diagnosis and treatment of certain respiratory the need for portable medical gases, such as oxygen concentrators, is rising as more people choose home-based healthcare. In order to ensure that chronic patients receive the oxygen therapy they require at home, this change places an emphasis on convenience and continuity of care. Home healthcare has become increasingly popular in recent years and is predicted to continue to grow. Many medical illnesses may now be successfully treated at home, including those that require ventilator assistance, mixed gas therapies, and long-term oxygen therapy. Additionally, it is anticipated that rising home healthcare reimbursement would support market expansion throughout the projection period. The Firesafe Cannula Valve, for example, was formally covered by Iowa Medicaid in November 2023 and was given the HCPCS number E0700 for reimbursement. In the event that the oxygen tubing downstream burns, this novel mechanism functions as a thermal fuse and instantly stops the oxygen supply. Thermal fuses must be installed in all home oxygen systems in the United Kingdom. Interestingly, the US has a 20-fold greater risk of death from oxygen-related flames than England, where installing firebreaks has been required since Drivers for the Medical Gas Market Numerous Medical Technology AdvancementsLaparoscopy and endoscopy are examples of minimally invasive (MI) surgical techniques that have been made possible by technological breakthroughs. Surgeons can execute treatments with fewer incisions, quicker patient recovery, and less tissue stress when medical gases like carbon dioxide are utilized to provide a clean operating field. Furthermore, more specialized and individualized treatment for respiratory problems is now possible because to developments in respiratory therapy equipment. The World Health Organization reports that asthma and other chronic respiratory diseases (CRDs) are on the rise worldwide, with 3.2 million deaths from COPD and 262 million cases of asthma in 2019. Advanced oxygen treatment equipment, such as portable oxygen delivery systems and oxygen concentrators, are used to supply medical gases like oxygen. Additionally, a number of developments in dermatology and cryosurgery have increased the use of medicinal gases, such as liquid nitrogen, to freeze and remove sick or aberrant tissue. The market is being driven by the regulated and focused treatment that cryotherapy equipment provides, which minimizes harm to nearby healthy Preference for Telemedicine and Home HealthcareMedical gases, such as oxygen, are frequently given to patients in their homes as part of home healthcare. To control their symptoms and enhance their quality of life, patients with long-term respiratory diseases like COPD need oxygen treatment. Medical oxygen gases are in greater demand as a result of the shift toward home healthcare, which enables patients to obtain oxygen therapy without the need for extended hospital stays. Furthermore, nebulization, pain relief, and respiratory therapies are only a few of the uses for medical gases that go beyond oxygen therapy. As a result of this trend, fewer extended hospital stays are required, which raises the requirement for medical as cardiovascular disorders are thought to cause 17.9 million deaths worldwide each year, medicinal gases - such as oxygen - are essential for treating associated ailments, which raises the need for at-home therapies. The need for medical gases is further increased by the growth of telemedicine and home healthcare, which enables patients to receive a greater variety of medical gas treatments in the convenience of their own Rates of Chronic Conditions, Including Heart and Respiratory ConditionsMedical gases like oxygen are necessary for respiratory support because to the rising prevalence of respiratory conditions such asthma, interstitial lung disorders, and chronic obstructive pulmonary disease (COPD). Chronic respiratory disorders (CRDs), such as asthma, interstitial lung diseases, and chronic obstructive pulmonary disease (COPD), are on the rise, according to the World Health Organization (WHO). According to the Global Asthma Report, asthma affects an estimated 262 million people globally, and COPD alone was responsible for almost 3.2 million deaths in treatment is necessary for patients who have trouble breathing in order to keep their blood oxygen levels sufficient and to relieve their symptoms. Furthermore, medicinal gases are frequently needed for diagnostic and therapeutic purposes in cardiovascular illnesses, such as heart failure, coronary artery disease, and hypertension. In order to ensure patient comfort and stability during cardiovascular procedures, nitrous oxide is used as an anesthetic agent. Additionally, medicinal gases are essential for palliative care for individuals with chronic illnesses that have in the Medical Gas Market Stringent Regulatory ComplianceBecause medical gases are essential to patient care and safety, the market is subject to strict regulatory compliance. To guarantee that medical gases fulfill therapeutic needs, regulatory agencies impose stringent criteria for purity, labeling, packing, and transportation. Operational complexity can be further increased by the constant monitoring, certification procedures, and thorough paperwork that are frequently required to comply with these rules. To maintain compliance, manufacturers must spend more on qualified staff and sophisticated quality control systems, which raises prices. Furthermore, managing disparate regional restrictions might make international distribution plans more difficult. Although these regulations guarantee patient safety and product dependability, they also place a financial and logistical strain on manufacturers, particularly newly established smaller Production and Storage CostsComplex infrastructure and procedures are needed to produce and store medicinal gases, which raises supply chain costs. To guarantee purity and safety, the gases need to be produced under exacting circumstances, which calls for cutting-edge technology and strict adherence to regulations. Energy-intensive systems are needed for compression and liquefaction, and storage facilities need to be built to withstand temperature changes, pollution, and leakage. Specialized, frequently temperature-controlled containers that adhere to stringent rules are also necessary for the transportation of these gases. Long-term costs are further increased by continuing storage system monitoring and maintenance. These elements work together to make medical gases far more expensive to produce, handle, and distribute than many other medical supplies, which puts a strain on both healthcare providers and suppliers. Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Revenue Analysis Air Liquide Linde Plc Atlas Copco Group Inox-Air Products Inc. Taiyo Nippon Sanso Corporation Matheson Tri-Gas, Inc. Horiba Group Sol India Private Limited Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $14.41 Billion Forecasted Market Value (USD) by 2033 $28.61 Billion Compound Annual Growth Rate 7.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Medical Gas Market5.1 Historical Market Trends5.2 Market Forecast6. Medical Gas Market Share Analysis6.1 By Product6.2 By Application6.3 By End Use6.4 By Countries7. Product7.1 Pure Gases7.2 Gas Mixtures8. Application8.1 Therapeutics8.2 Diagnostics8.3 Others9. End Use9.1 Hospitals9.2 Pharmaceutical & Biotechnology Companies9.3 Ambulatory Surgical Centers9.4 Diagnostic & Research Laboratories9.5 Academic & Research Institutes9.6 Home Healthcare10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 South Korea10.3.5 Thailand10.3.6 Malaysia10.3.7 Indonesia10.3.8 Australia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 Saudi Arabia10.5.2 UAE10.5.3 South Africa11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Medical Gas Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Jeep owner Stellantis says has turned corner
Jeep owner Stellantis says has turned corner

Yahoo

time26 minutes ago

  • Yahoo

Jeep owner Stellantis says has turned corner

Jeep owner Stellantis said Tuesday it sees sales revenue and profitability rebounding in the second half of the year despite taking a 1.5-billion-euro ($1.7-billion) hit from US tariffs. The 15-brand group that also includes Peugeot, Citroen and Fiat, confirmed the preliminary announcement it made last week of a 2.3-billion-euro net loss in the first half of the year, as sales in North America continued to slump on an annual comparison. But Stellantis's new chief executive, Antonio Filosa, said the automaker is beginning to see "gradual improvement" in sales volumes and revenues on a sequential basis "despite intensifying external headwinds". Like some of its rivals, Stellantis had suspended financial guidance due to the uncertainty surrounding US tariffs and regulatory changes, but it said it now sees an increase in revenues in the second half of the year as well as operating profit margin in the low single digits. Under former chief executive Carlos Tavares the company had long targeted a double-digit margin, but it fell to just 0.7 percent. Stellantis also put a figure on the impact of the 25 percent US tariffs on auto imports: 1.5 billion euros for 2025 overall, of which 300 million euros was incurred in the first half of the year. Part of the turnaround was taking a 3.3-billion-euro charge, which Stellantis announced last week, which took into account the costs to adapting to new US regulations. Trump's massive tax and spending legislation, approved earlier this month, removed the penalties for not respecting the so-called CAFE fuel economy targets, meaning automakers can produce and sell more higher polluting cars in the United States. This is allowing Stellantis to bring back a number of models, including pickup trucks and muscle cars, that had been phased out because of their internal combustion engines to meet fuel efficiency targets and pollution limits. Stellantis said this and a "product wave" of 10 new models this year would support future performance. Company veteran Filosa took over as chief executive in June, half a year after Tavares left, in large part to haemorrhaging sales in North America. Filosa has shook up the company's management team and moved swiftly to jettison two billion euros of programmes considered as having poor prospects to quickly turn a profit, such as hydrogen fuel cell vehicles. Stellantis shares slumped 3.7 percent in trading on the Paris stock exchange, which was up 0.5 percent overall. Stellantis shares have lost around 37 percent since the start of the year and 70 percent from their peak early last year. tsz/rl/yad Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store